MBRX insider filings
Moleculin Biotech, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-08-05. Screen MBRX transaction legs live →
Insider transaction summary — last 90 days
2026-07-10 to 2026-10-08, from the filings listed below: 3 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 3 filings by 3 insiders — 999,999 shares.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 3.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| KLEMP WALTER V — CEO and President, Director | 1 | 1 leg · 533,333 sh | — | 1 |
| Foster Jonathan P. — Chief Financial Officer | 1 | 1 leg · 293,333 sh | — | 1 |
| PICKER DONALD H — Chief Science Officer | 1 | 1 leg · 173,333 sh | — | 1 |
Recent insider filings — Moleculin Biotech, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-05 | 4 | PICKER DONALD H — Chief Science Officer | Purchase (P): 173,333 · Purchase (P): 519,999 (derivative) | EDGAR |
| 2026-08-05 | 4 | KLEMP WALTER V — CEO and President, Director | Purchase (P): 533,333 · Grant/award (A): 1,599,999 (derivative) | EDGAR |
| 2026-08-05 | 4 | Foster Jonathan P. — Chief Financial Officer | Purchase (P): 293,333 · Purchase (P): 879,999 (derivative) | EDGAR |
| 2026-06-24 | 4 | KLEMP WALTER V — CEO and President, Director | Option exercise (M): 150 · Tax withholding (F): 37 @ $2.88 · Option exercise (M): 360 · Tax withholding (F): 88 @ $3.12 · Option exercise (M): 150 (derivative) @ $0 · Option exercise (M): 360 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Foster Jonathan P. — Chief Financial Officer | Option exercise (M): 109 · Tax withholding (F): 31 @ $2.88 · Option exercise (M): 174 · Tax withholding (F): 41 @ $3.12 · Option exercise (M): 109 (derivative) @ $0 · Option exercise (M): 174 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | PICKER DONALD H — Chief Science Officer | Option exercise (M): 44 · Tax withholding (F): 13 @ $2.88 · Option exercise (M): 71 · Tax withholding (F): 21 @ $3.12 · Option exercise (M): 44 (derivative) @ $0 · Option exercise (M): 71 (derivative) @ $0 | EDGAR |
| 2025-11-14 | 4 | KLEMP WALTER V — CEO and President, Director | Grant/award (A): 830,000 (derivative) · Grant/award (A): 750,000 (derivative) | EDGAR |
| 2025-11-14 | 4 | Yan Joy — Director | Grant/award (A): 150,000 (derivative) | EDGAR |
| 2025-11-14 | 4 | George Robert E. — Director | Grant/award (A): 150,000 (derivative) | EDGAR |
| 2025-11-14 | 4 | Climaco John M — Director | Grant/award (A): 150,000 (derivative) | EDGAR |
| 2025-11-14 | 4 | Foster Jonathan P. — EVP & CFO | Grant/award (A): 600,000 (derivative) · Grant/award (A): 400,000 (derivative) | EDGAR |
| 2025-11-14 | 4 | Cermak Elizabeth — Director | Grant/award (A): 150,000 (derivative) | EDGAR |
| 2025-11-14 | 4 | PICKER DONALD H — CSO | Grant/award (A): 200,000 (derivative) · Grant/award (A): 200,000 (derivative) | EDGAR |
| 2025-11-14 | 4 | CANNON MICHAEL D — Director | Grant/award (A): 150,000 (derivative) | EDGAR |
| 2025-11-06 | 4 | KLEMP WALTER V — CEO and President, Director | Option exercise (M): 28,750 · Tax withholding (F): 7,001 @ $0.50 · Option exercise (M): 28,750 (derivative) @ $0 | EDGAR |
| 2025-11-06 | 4 | Foster Jonathan P. — Chief Financial Officer | Option exercise (M): 20,625 · Option exercise (M): 5,023 @ $0.50 · Option exercise (M): 20,625 (derivative) @ $0 | EDGAR |
| 2025-11-06 | 4 | PICKER DONALD H — Chief Science Officer | Option exercise (M): 8,750 · Tax withholding (F): 2,131 @ $0.50 · Option exercise (M): 8,750 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | KLEMP WALTER V — CEO and President, Director | Option exercise (M): 3,750 · Tax withholding (F): 914 @ $0.27 · Option exercise (M): 8,990 · Tax withholding (F): 2,190 @ $0.27 · Purchase (P): 675,675 @ $0.37 · Option exercise (M): 3,750 (derivative) @ $0 · +2 more | EDGAR |
| 2025-06-23 | 4 | Foster Jonathan P. — Chief Financial Officer | Option exercise (M): 2,711 · Tax withholding (F): 661 @ $0.27 · Option exercise (M): 4,328 · Tax withholding (F): 1,054 @ $0.27 · Purchase (P): 270,270 @ $0.37 · Option exercise (M): 2,711 (derivative) @ $0 · +2 more | EDGAR |
| 2025-06-23 | 4 | PICKER DONALD H — Chief Science Officer | Option exercise (M): 1,078 · Tax withholding (F): 263 @ $0.27 · Option exercise (M): 1,766 · Tax withholding (F): 430 @ $0.27 · Option exercise (M): 1,078 (derivative) @ $0 · Option exercise (M): 1,766 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | KLEMP WALTER V — CEO and President, Director | Option exercise (M): 1,667 · Tax withholding (F): 406 @ $0.69 · Option exercise (M): 1,667 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Foster Jonathan P. — Chief Financial Officer | Option exercise (M): 833 · Tax withholding (F): 203 @ $0.69 · Option exercise (M): 833 (derivative) @ $0 | EDGAR |
| 2024-11-06 | 4 | Yan Joy — Director | Grant/award (A): 10,000 (derivative) | EDGAR |
| 2024-11-06 | 4 | George Robert E. — Director | Grant/award (A): 10,000 (derivative) | EDGAR |
| 2024-11-06 | 4 | KLEMP WALTER V — CEO and President, Director | Grant/award (A): 100,000 (derivative) · Grant/award (A): 115,000 (derivative) · Grant/award (A): 43,590 (derivative) | EDGAR |
| 2024-11-06 | 4 | Climaco John M — Director | Grant/award (A): 10,000 (derivative) | EDGAR |
| 2024-11-06 | 4 | Foster Jonathan P. — Chief Financial Officer | Grant/award (A): 65,000 (derivative) · Grant/award (A): 82,500 (derivative) · Grant/award (A): 19,180 (derivative) | EDGAR |
| 2024-11-06 | 4 | Cermak Elizabeth — Director | Grant/award (A): 10,000 (derivative) | EDGAR |
| 2024-11-06 | 4 | PICKER DONALD H — Chief Science Officer | Grant/award (A): 40,000 (derivative) · Grant/award (A): 35,000 (derivative) · Grant/award (A): 5,744 (derivative) | EDGAR |
| 2024-11-06 | 4 | CANNON MICHAEL D — Director | Grant/award (A): 10,000 (derivative) | EDGAR |
| 2024-07-05 | 4 | KLEMP WALTER V — CEO and President, Director | Option exercise (M): 982 · Tax withholding (F): 240 @ $3.57 · Option exercise (M): 982 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | KLEMP WALTER V — CEO and President, Director | Option exercise (M): 8,990 · Tax withholding (F): 2,190 @ $3.74 · Option exercise (M): 8,990 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | Foster Jonathan P. — Chief Financial Officer | Option exercise (M): 4,329 · Tax withholding (F): 1,053 @ $3.74 · Option exercise (M): 4,329 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | PICKER DONALD H — Chief Science Officer | Option exercise (M): 1,766 · Tax withholding (F): 524 @ $3.74 · Option exercise (M): 1,766 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | KLEMP WALTER V — CEO and President, Director | Option exercise (M): 3,750 · Tax withholding (F): 914 @ $3.78 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Foster Jonathan P. — Chief Financial Officer | Option exercise (M): 2,712 · Tax withholding (F): 636 @ $3.78 · Option exercise (M): 2,712 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | PICKER DONALD H — Chief Science Officer | Option exercise (M): 1,078 · Tax withholding (F): 320 @ $3.78 · Option exercise (M): 1,078 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | KLEMP WALTER V — CEO and President, Director | Option exercise (M): 1,667 · Tax withholding (F): 406 @ $4.14 · Option exercise (M): 1,667 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Foster Jonathan P. — Chief Financial Officer | Option exercise (M): 834 · Tax withholding (F): 196 @ $4.14 · Option exercise (M): 834 (derivative) @ $0 | EDGAR |
| 2023-12-27 | 4 | George Robert E. — Director | Purchase (P): 14,493 @ $0.69 | EDGAR |
| 2023-12-27 | 4 | KLEMP WALTER V — CEO and President, Director | Purchase (P): 188,404 @ $0.69 | EDGAR |
| 2023-12-27 | 4 | Foster Jonathan P. — Chief Financial Officer | Purchase (P): 28,986 @ $0.69 | EDGAR |
| 2023-07-13 | 4 | KLEMP WALTER V — CEO and President, Director | Option exercise (M): 13,204 · Tax withholding (F): 3,216 @ $0.59 · Option exercise (M): 13,204 (derivative) @ $0 | EDGAR |
| 2023-07-05 | 4 | KLEMP WALTER V — CEO and President, Director | Option exercise (M): 14,717 · Tax withholding (F): 3,584 @ $0.58 · Option exercise (M): 14,717 (derivative) @ $0 | EDGAR |
| 2023-06-26 | 4 | KLEMP WALTER V — CEO and President, Director | Grant/award (A): 400,000 (derivative) · Grant/award (A): 539,375 (derivative) | EDGAR |
| 2023-06-26 | 4 | Foster Jonathan P. — Chief Financial Officer | Grant/award (A): 150,000 (derivative) · Grant/award (A): 259,688 (derivative) | EDGAR |
| 2023-06-26 | 4 | PICKER DONALD H — Chief Science Officer | Grant/award (A): 100,000 (derivative) · Grant/award (A): 105,938 (derivative) | EDGAR |
| 2023-06-22 | 4 | KLEMP WALTER V — CEO and President, Director | Option exercise (M): 56,250 · Tax withholding (F): 13,697 @ $0.57 · Option exercise (M): 56,250 (derivative) @ $0 | EDGAR |
| 2023-06-22 | 4 | Foster Jonathan P. — Chief Financial Officer | Option exercise (M): 40,667 · Tax withholding (F): 9,676 @ $0.57 · Option exercise (M): 40,667 (derivative) @ $0 | EDGAR |
| 2023-06-22 | 4 | PICKER DONALD H — Chief Science Officer | Option exercise (M): 16,167 · Tax withholding (F): 4,267 @ $0.57 · Option exercise (M): 16,167 (derivative) @ $0 | EDGAR |
Recent 8-K events — Moleculin Biotech, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-05 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-29 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-28 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-25 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-23 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-18 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-09-14 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-31 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — Moleculin Biotech, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-297776 (S-1) — latest: Amendment (S-1/A), filed 2026-07-31
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MBRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →